22940 Federal Register / Vol. 74, No. 93 / Friday, May 15, 2009 / Notices 

* The Standards Council of Canada (SCC) voted 

to end its Laboratory Accreditation Program for 

Substance Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that program were 

accredited to conduct forensic urine drug testing as 

required by U.S. Department of Transportation 

(DOT) regulations. As of that date, the certification 

of those accredited Canadian laboratories will 

continue under DOT authority. The responsibility 

for conducting quarterly performance testing plus 

periodic on-site inspections of those LAPSAaccredited laboratories was transferred to the U.S. 

HHS, with the HHS’ NLCP contractor continuing to 

have an active role in the performance testing and 

laboratory inspection processes. Other Canadian 

laboratories wishing to be considered for the NLCP 

may apply directly to the NLCP contractor just as 

U.S. laboratories do. 

Upon finding a Canadian laboratory to be 

qualified, HHS will recommend that DOT certify 

the laboratory (Federal Register, July 16, 1996) as 

meeting the minimum standards of the Mandatory 

Guidelines published in the Federal Register on 

April 13, 2004 (69 FR 19644). After receiving DOT 

certification, the laboratory will be included in the 

monthly list of HHS-certified laboratories and 

participate in the NLCP certification maintenance 

program. 

23236, 804–378–9130, (Formerly: 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.). 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387. 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986, 

(Formerly: Roche Biomedical 

Laboratories, Inc.). 

Laboratory Corporation of America 

Holdings, 1904 Alexander Drive, 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984, 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group). 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671, 866–827–8042/ 

800–233–6339, (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center). 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 

66219, 913–888–3927/800–873–8845, 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.). 

Maxxam Analytics,* 6740 Campobello 

Road, Mississauga, ON, Canada L5N 

2L8, 905–817–5700, (Formerly: 

Maxxam Analytics Inc., NOVAMANN 

(Ontario), Inc.). 

MedTox Laboratories, Inc., 402 W. 

County Road D, St. Paul, MN 55112, 

651–636–7466/800–832–3244. 

MetroLab-Legacy Laboratory Services, 

1225 NE 2nd Ave., Portland, OR 

97232, 503–413–5295/800–950–5295. 

Minneapolis Veterans Affairs Medical 

Center, Forensic Toxicology 

Laboratory, 1 Veterans Drive, 

Minneapolis, MN 55417, 612–725– 

2088. 

National Toxicology Laboratories, Inc., 

1100 California Ave., Bakersfield, CA 

93304, 661–322–4250/800–350–3515. 

One Source Toxicology Laboratory, Inc., 

1213 Genoa-Red Bluff, Pasadena, TX 

77504, 888–747–3774, (Formerly: 

University of Texas Medical Branch, 

Clinical Chemistry Division; UTMB 

Pathology-Toxicology Laboratory). 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311, 

800–328–6942, (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory). 

Pathology Associates Medical 

Laboratories, 110 West Cliff Dr., 

Spokane, WA 99204, 509–755–8991/ 

800–541–7891x7. 

Phamatech, Inc., 10151 Barnes Canyon 

Road, San Diego, CA 92121, 858–643– 

5555. 

Quest Diagnostics Incorporated, 3175 

Presidential Dr., Atlanta, GA 30340, 

770–452–1590/800–729–6432, 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories). 

Quest Diagnostics Incorporated, 400 

Egypt Road, Norristown, PA 19403, 

610–631–4600/877–642–2216, 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories). 

Quest Diagnostics Incorporated, 7600 

Tyrone Ave., Van Nuys, CA 91405, 

866–370–6699/818–989–2521, 

(Formerly: SmithKline Beecham 

Clinical Laboratories). 

S.E.D. Medical Laboratories, 5601 Office 

Blvd., Albuquerque, NM 87109, 505– 

727–6300/800–999–5227. 

South Bend Medical Foundation, Inc., 

530 N. Lafayette Blvd., South Bend, 

IN 46601, 574–234–4176 x276. 

Southwest Laboratories, 4625 E. Cotton 

Center Boulevard, Suite 177, Phoenix, 

AZ 85040, 602–438–8507/800–279– 

0027. 

St. Anthony Hospital Toxicology 

Laboratory, 1000 N. Lee St., 

Oklahoma City, OK 73101, 405–272– 

7052. 

STERLING Reference Laboratories, 2617 

East L Street, Tacoma, Washington 

98421, 800–442–0438. 

Toxicology & Drug Monitoring 

Laboratory, University of Missouri 

Hospital & Clinics, 301 Business Loop 

70 West, Suite 208, Columbia, MO 

65203, 573–882–1273. 

Toxicology Testing Service, Inc., 5426 

N.W. 79th Ave., Miami, FL 33166, 

305–593–2260. 

US Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755– 

5235, 301–677–7085. 

The following laboratory voluntarily 

withdrew from the NLCP on March 31, 

2009: 

Sparrow Health System, Toxicology 

Testing Center, St. Lawrence Campus, 

1210 W. Saginaw, Lansing, MI 48915, 

517–364–7400, (Formerly: St. 

Lawrence Hospital & Healthcare 

System). 

Dated: May 8, 2009. 

Elaine Parry, 

Director, Office of Program Services, 

SAMHSA. 

[FR Doc. E9–11374 Filed 5–14–09; 8:45 am] 

BILLING CODE 4160–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

National Advisory Committee on Rural 

Health and Human Services; Notice of 

Meeting 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), notice is hereby given 

that the following committee will 

convene its sixty-second meeting. 

Name: National Advisory Committee on 

Rural Health and Human Services 

Dates and Times: June 9, 2009, 9 a.m.— 

4:45 p.m. 

June 10, 2009, 8:45 a.m.—3 p.m. 

June 11, 2009, 8:45 a.m.—11 a.m. 

Place: Hampton Inn, 

1720 Rapp Street, 

Rapid City, South Dakota 57701, 

Phone: 605–348–1911. 

Status: The meeting will be open to the 

public. 

Purpose: The National Advisory 

Committee on Rural Health and Human 

Services provides advice and 

recommendations to the Secretary with 

respect to the delivery, research, 

development and administration of health 

and human services in rural areas. 

Agenda: Tuesday morning, at 9 a.m., the 

meeting will be called to order by the 

Chairperson of the Committee, the Honorable 

David Beasley. The first presentation will be 

an overview of rural South Dakota by Dr. 

Sidney Goss, Professor of Demography, South 

Dakota School of Mines and Technology. The 

Committee will be formally welcomed by the 

South Dakota Office of Rural Health, Sandra 

Durick, Director. The Committee will hear 

presentations on the three chosen 

Federal Register / Vol. 74, No. 93 / Friday, May 15, 2009 / Notices 22941 

Subcommittee topics. The first panel will 

focus on Primary Care Workforce. The 

confirmed speakers are Dr. Bruce Vogt, Chair 

of Family Medicine, University of South 

Dakota; Dr. Charles Hart, CEO of Regional 

Health System; and Josie Peterson, South 

Dakota PCO Director. The second panel is 

Home-Based Care Options for Seniors. The 

confirmed speakers are Deb Bowman, 

Committee Member and Secretary of the 

South Dakota Department of Social Services; 

and Senator Jean Hunhoff, head of home care 

services at Yankton, South Dakota, and 

member of the task force on Meeting the 

Continuum of Care Needs of the Elderly in 

South Dakota. The final panel of the day is 

Health Care Provider Integration. The 

confirmed speakers are Tom Dean, MedPAC 

Member; Scot Graff, Community Healthcare 

Association of the Dakotas; and Matt 

Michaels, Health Care Attorney. After the 

panel discussions, the Committee Chair will 

give an overview of the site visits. The 

Tuesday meeting will close at 4:45 p.m. 

Wednesday morning, at 8:45 a.m., the 

Committee will break into Subcommittees 

and depart to the site visits. The Primary 

Care Workforce Subcommittee will visit 

Phillip Health Services in Philip, South 

Dakota. The Home-Based Care Options for 

Seniors Subcommittee will visit Regional 

Health Hospice Center in Rapid City, South 

Dakota. The Health Care Provider Integration 

Subcommittee will visit Custer Regional 

Hospital in Custer, South Dakota. 

Transportation to the site visits will not be 

provided to the public. The Subcommittees 

will return to Rapid City, South Dakota at 3 

p.m. The Wednesday meeting will close at 3 

p.m. 

The final session will be convened on 

Thursday morning at 8:45 a.m. The meeting 

will open with a review of the Subcommittee 

site visits. The staff of the Office of Rural 

Health Policy will provide an update on the 

Department of Health and Human Services. 

The Committee will draft a letter to the 

Secretary or Designee and discuss the 

September meeting. 

For Further Information Contact: Anyone 

requiring information regarding the 

Committee should contact Jennifer Chang, 

MPH, Executive Secretary, National Advisory 

Committee on Rural Health and Human 

Services, Health Resources and Services 

Administration, Parklawn Building, Room 

9A–55, 5600 Fishers Lane, Rockville, MD 

20857, Telephone (301) 443–0835, Fax (301) 

443–2803. 

Persons interested in attending any portion 

of the meeting should contact Michele Pray 

Gibson, Office of Rural Health Policy 

(ORHP), Telephone (301) 443–0835. The 

Committee meeting agenda will be posted on 

ORHP’s Web site http:// 

www.ruralhealth.hrsa.gov. 

Dated: April 11, 2009. 

Alexandra Huttinger, 

Director, Division of Policy Review and 

Coordination. 

[FR Doc. E9–11441 Filed 5–14–09; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0664] 

Pediatric Advisory Committee; Notice 

of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Pediatric 

Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on Tuesday, June 23, 2009, from 

8:30 a.m. to 5 p.m. 

Location: Hilton Washington DC/ 

Rockville Executive Meeting Center, 

Plaza Ballroom, 1750 Rockville Pike, 

Rockville, MD 20852. 

Contact Person: Carlos Pen ̃ a, Office of 

Science and Health Coordination, Office 

of the Commissioner (HF–33), Food and 

Drug Administration, 5600 Fishers Lane 

(for express delivery, rm. 14B–08), 

Rockville, MD 20857, 301–827–3340, or 

by e-mail: carlos.pen ̃ a@fda.hhs.gov or 

FDA Advisory Committee Information 

Line, 1–800–741–8138 (301–443–0572 

in the Washington, DC area), code 

8732310001. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On June 23, 2009, the 

Pediatric Advisory Committee will 

review and discuss reports by the 

agency, as mandated by the Best 

Pharmaceuticals for Children Act and 

the Pediatric Research Equity Act, for 

ALVESCO (ciclesonide), ANDROGEL 

(testosterone), ASMANEX (mometasone 

furoate), COMBIGAN (brimonidine/ 

timolol), DEPAKOTE (divalproex 

sodium), DERMA–SMOOTHE F/S 

(fluocinolone acetate), DIOVAN 

(valsartan), HEPSERA (adefovir 

dipivoxil), INSPRA (eplerenone), 

MOXATAG (amoxicillin), OMNARIS 

(ciclesonide), and ZOMETA (zoledronic 

acid). 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ohrms/ 

dockets/ac/acmenu.htm, click on the 

year 2009 and scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before June 9, 2009. Oral 

presentations from the public will be 

scheduled between approximately 1 

p.m. and 2 p.m. Those desiring to make 

formal oral presentations should notify 

the contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before June 1, 2009. Time allotted for 

each presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by June 2, 2009. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Carlos Pen ̃ a 

at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/oc/advisory/ 

default.htm for procedures on public 

conduct during advisory committee 

meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2).